H.C. Wainwright Reiterates Buy Rating on Brainsway (BWAY)

Fri, 30 Oct 2026 06:44:03 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $19.00 price target on Brainsway (NASDAQ: BWAY).

The analyst commented: "BrainsWay recently reported further expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS in the treatment of patients suffering from obsessive compulsive disorder (OCD). Following this latest expansion, more than 118M Americans are now covered under insurance policies that provide access to BrainsWay Deep TMS for OCD, marking another important milestone in the company's ongoing efforts to broaden patient access to innovative, evidence-based mental health treatments. As the first company to

BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026

Wed, 28 Oct 2026 08:00:00 -0400

BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2026 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 10, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

US Conference Call Dial-In & Webcast Information

Form 6-K/A Brainsway Ltd. For: Oct 26

Mon, 26 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261026/27233894.html

BrainsWay OCD treatment now covered for 118 million Americans

Mon, 26 Oct 2026 07:32:36 -0400

BrainsWay Ltd. (NASDAQ: BWAY) announced that U.S. insurance coverage for its Deep TMS treatment of obsessive-compulsive disorder (OCD) has expanded to more than 118 million Americans.

The company states it was the first to receive FDA clearance for a noninvasive brain stimulation treatment for OCD and says it is the only TMS company to have published data from a randomized, placebo-controlled multicenter pivotal study on its device for that indication.

"Reaching more than 118 million covered lives represents meaningful progress in expanding access to Deep TMS for patients living with this challenging condition," said Hadar Levy, Chief Executive Officer of BrainsWay. "We

BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

Mon, 26 Oct 2026 07:30:00 -0400

BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS™ in the treatment of patients suffering from obsessive compulsive disorder (OCD).

With this latest expansion, more than 118 million Americans are now covered under insurance policies that provide access to BrainsWay Deep TMS for OCD, marking another important milestone in the Company's ongoing efforts to broaden

BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

Mon, 26 Oct 2026 07:30:00 -0400

Form 6-K Brainsway Ltd. For: Oct 26

Mon, 26 Oct 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20261026/27230677.html

Form 6-K Brainsway Ltd. For: Nov 25

Wed, 21 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261021/27216276.html

H.C. Wainwright Reiterates Buy Rating on Brainsway (BWAY)

Tue, 20 Oct 2026 06:56:49 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $19.00 price target on Brainsway (NASDAQ: BWAY).

The analyst commented: "This morning, BrainsWay announced a strategic collaboration with Inland Psychiatric Medical Group (IPMG), an established provider of comprehensive behavioral health services across Southern California. IPMG operates a multidisciplinary behavioral health practice serving patients throughout Southern California, including in Riverside, San Bernardino, Los Angeles, and Orange Counties. Its comprehensive clinical services include psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment, and clinical research. The collaboration with BrainsWay includes a multi-system order of BrainsWay Deep TMS systems planned for installation at IPMG clinics,

Form 6-K Brainsway Ltd. For: Oct 19

Mon, 19 Oct 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20261019/27202776.html

BrainsWay partners with Inland Psychiatry on Deep TMS expansion

Mon, 19 Oct 2026 07:31:45 -0400

BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced a collaboration with Inland Psychiatric Medical Group (IPMG), a behavioral health provider operating across Southern California, according to a company press release.

The agreement includes a multisystem order of BrainsWay Deep TMS devices planned for installation at IPMG clinics. The two organizations also intend to explore scientific, clinical, and research projects related to interventional psychiatry.

IPMG operates across Riverside, San Bernardino, Los Angeles, and Orange Counties, offering services that include psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment, and clinical research.

BrainsWay's Deep TMS system uses a magnetic field delivered through a helmet-mounted coil to stimulate

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

Mon, 19 Oct 2026 07:30:00 -0400

BURLINGTON, Mass. and JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced a strategic collaboration with Inland Psychiatric Medical Group (“IPMG”), an established provider of comprehensive behavioral health services across Southern California.

IPMG operates a multidisciplinary behavioral health practice serving patients throughout Southern California, including in Riverside, San Bernardino, Los Angeles, and Orange Counties. Its comprehensive clinical services include psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment, and clinical research.

The collaboration with BrainsWay

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

Mon, 19 Oct 2026 07:30:00 -0400

The collaboration with BrainsWay

BrainsWay says coverage for its SWIFT protocol tops 70 million lives

Tue, 13 Oct 2026 07:32:00 -0400

BrainsWay Ltd. (NASDAQ: BWAY) announced that U.S. medical policies providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol now extend to over 70 million covered lives.

The company said the expansion reflects continued momentum in favorable policy changes for Deep TMS broadly, including for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).

"This announcement highlights the increasing pathways toward SWIFT adoption," said Hadar Levy, Chief Executive Officer of BrainsWay. "Our progress in this area is enabled by the strong and increasing body of data demonstrating high efficacy and durability of our accelerated SWIFT protocol for depression, as well

Form 6-K Brainsway Ltd. For: Oct 13

Tue, 13 Oct 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20261013/27177081.html

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

Tue, 13 Oct 2026 07:30:00 -0400

BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.

With this update, there are now over 70 million covered lives in the U.S. with access to policies covering SWIFT. The announcement comes amid continued momentum in favorable policy changes for Deep TMS generally, including for the treatment major depressive disorder (MDD) and obsessive-compulsive disorder

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

Tue, 13 Oct 2026 07:30:00 -0400

Form 6-K Brainsway Ltd. For: Jun 30

Tue, 29 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260929/27122327.html

Brainsway (BWAY) PT Raised to $19 at H.C. Wainwright

Mon, 31 Aug 2026 06:53:31 -0400

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Brainsway (NASDAQ: BWAY) to $19.00 (from $17.00) while maintaining a Buy rating.

The analyst commented: "Late last week, BrainsWay reported the publication of new peer-reviewed data showing significant reductions in suicidal ideation among patients with major depressive disorder (MDD) treated with Deep Transcranial Magnetic Stimulation (Deep TMS). The publication, entitled “Effects of H-coil TMS on suicidality in major depression: A secondary analysis of data from a multi-site randomized trial comparing accelerated to once-a-day stimulation,” was published in the Journal of Affective Disorders. After factoring in our forecast revisions and the moderate

Brainsway (BWAY) PT Raised to $19 at H.C. Wainwright

Mon, 31 Aug 2026 06:53:31 -0400

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Brainsway (NASDAQ: BWAY) to $19.00 (from $17.00) while maintaining a Buy rating.

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

Thu, 27 Aug 2026 07:30:00 -0400

BURLINGTON, Mass. and JERUSALEM, Aug. 27, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of new peer-reviewed data demonstrating significant reductions in suicidal ideation among patients with Major Depressive Disorder (MDD) treated with Deep Transcranial Magnetic Stimulation (Deep TMS™).

The publication, entitled “Effects of H-coil TMS on suicidality in major depression: A secondary analysis of data from a multisite randomized trial comparing accelerated to once-a-day stimulation,” was published in the Journal of Affective Disorders. The

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

Thu, 27 Aug 2026 07:30:00 -0400

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

Thu, 27 Aug 2026 07:30:00 -0400

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

Thu, 27 Aug 2026 07:30:00 -0400

StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Brainsway (BWAY)

BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026

Form 6-K/A Brainsway Ltd. For: Oct 26

BrainsWay OCD treatment now covered for 118 million Americans

BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

Form 6-K Brainsway Ltd. For: Oct 26

Form 6-K Brainsway Ltd. For: Nov 25

H.C. Wainwright Reiterates Buy Rating on Brainsway (BWAY)

Form 6-K Brainsway Ltd. For: Oct 19

BrainsWay partners with Inland Psychiatry on Deep TMS expansion

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

BrainsWay says coverage for its SWIFT protocol tops 70 million lives

Form 6-K Brainsway Ltd. For: Oct 13

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

Form 6-K Brainsway Ltd. For: Jun 30

Brainsway (BWAY) PT Raised to $19 at H.C. Wainwright

Brainsway (BWAY) PT Raised to $19 at H.C. Wainwright

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation